The U.S. Food and Drug Administration will give priority review to a New Drug Application that GW Pharmaceuticals submitted for its cannabis-based therapy for two difficult-to-treat epilepsies that appear in childhood. U.S. regulators” decision to review the application on an accelerated timetable follows GW’s submission  of a Marketing Authorization Application to…
News
Sudden unexplained death in epilepsy (SUDEP) in patients with Dravet syndrome can be caused by breathing abnormalities associated with an epileptic seizure, which may slow down the heart rate and eventually lead to death, a study shows.
Recent Posts
- Seizures are now part of my daughter’s playtime with her baby doll
- Long-term study finds no new safety concerns with Dravet therapy
- Her name is Sister Bear Potato, and she is exactly what we needed
- Our family’s experience with vagus nerve stimulation for Dravet seizures
- Dravet syndrome drug moves forward after Phase 3 enrollment